Patient preferences for ovarian cancer treatment with PARP inhibitors
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 3 or 4 high-grade serous or endometrioid ovarian cancer (or are suspected to have it).
- You can give oral consent and fill out questionnaires in English.
- You are eligible to receive a PARP inhibitor (a type of maintenance therapy).
- You are willing to have HRD testing (a test that looks at how your cancer cells repair DNA).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how eating habits may affect the outlook for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor. By understanding your diet, researchers hope to find ways to improve treatment results.
This trial studies how well older adults (70+) with advanced ovarian cancer tolerate PARP inhibitors in real-world care. It aims to see if the standard dose works for this age group.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This trial tests whether a supervised exercise and nutrition program can improve well-being for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor after finishing their first round of chemotherapy. Participation may help manage side effects and support overall health.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.